REGN Stock Regeneron Pharmaceuticals, Inc.
STRONG BUY US · NasdaqGSImmunology and ophthalmology franchises provide strong cash flow and pipeline optionality.
Future value: $865.48 (+7.16%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Pipeline catalysts and durable specialty-pharma demand.
- ▸Above 50-day MA (+2.05%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (81.8% of range) — strength
Is REGN a buy right now?
Trend: REGN is trading above the 50-day average (+2.05%), RSI 48 — neutral momentum, with a 3-month return of +16.18%.
Valuation & quality: Regeneron Pharmaceuticals, Inc. trades on a trailing P/E of 20.0, forward P/E 12.9, PEG 1.37, price-to-book 2.56; fundamentals show net margin 27.9%, return on equity 14.0%, revenue growth 16.7% year on year.
Analyst consensus: 27 analysts have a mean 12-month price target of $867.33 (+7.4% vs the last close; range $730.00 – $1030.00), consensus rating “buy”.
Income: trailing dividend yield 0.47%.
Our screen: STRONG BUY (score 4) — Immunology and ophthalmology franchises provide strong cash flow and pipeline optionality.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -1.20% | -8.50% | -13.10% | +1.40% | +22.30% | +4.80% | -5.10% | +6.50% |
Fundamentals
Analyst price target
Technical signals
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Sector: Healthcare · Industry: Biotechnology · United States · 15,410 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.